Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04225468 · ClinicalTrials.gov registry record · NA

Safe Options for ACL Recovery

A NA study of Opioid Use and Anterior Cruciate Ligament Injuries, sponsored by Karen Derefinko, PhD.

Completed
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT04225468 is a NA study of Opioid Use and Anterior Cruciate Ligament Injuries that has completed, run by Karen Derefinko, PhD. The registered enrollment target is 120 participants, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04225468, a NA study of Opioid Use and Anterior Cruciate Ligament Injuries, has completed, sponsored by Karen Derefinko, PhD.

COMPLETED
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The purpose of the proposed work is to test a brief opioid exposure reduction program (ACL-OERP) designed to improve health literacy about opioid use following surgeries. This intervention is specifically designed to be used with patients (or for patients under 18, the patient and caregiver) undergoing Anterior Cruciate Ligament (ACL) reconstruction, a painful surgery that is often followed by at least 7 days of opioid medication.

Interventions

  • BEHAVIORAL ACL Opioid Exposure Reduction Program

Study Locations (1)

Tennessee

  • University of Tennessee Health Science Center - Memphis

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2020-02-12
Est. Completion 2022-06-03
Phase NA

Sponsor

Karen Derefinko, PhD

4 total trials

What the Registry Record Tells You About NCT04225468

The ClinicalTrials.gov registry entry for NCT04225468 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148,259-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The listed sponsor is Karen Derefinko, PhD, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Opioid Use appearing as the primary indexed condition, and to 1 intervention - of which ACL Opioid Exposure Reduction Program is the first listed.

NCT04225468 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT04225468 about?

NCT04225468 is a clinical study titled "Safe Options for ACL Recovery". The purpose of the proposed work is to test a brief opioid exposure reduction program (ACL-OERP) designed to improve health literacy about opioid use following surgeries. This intervention is specifically designed to be used with patients (or for patients under 18, the patient and caregiver) undergo...

What is the current status of trial NCT04225468?

This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2020-02-12. Estimated completion is 2022-06-03.

What conditions does trial NCT04225468 study?

This clinical trial studies the following conditions: Opioid Use, Anterior Cruciate Ligament Injuries.

What interventions are being tested in trial NCT04225468?

The interventions under investigation include: ACL Opioid Exposure Reduction Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT04225468?

This trial is sponsored by Karen Derefinko, PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04225468 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.